Aquestive Therapeutics (AQST) Change in Accured Expenses (2017 - 2026)

Aquestive Therapeutics' Change in Accured Expenses history runs 10 years deep, the most recent figure standing at -$2.8 million for Q1 2026.

• On a quarterly basis, Change in Accured Expenses fell 0.97% year-over-year to -$2.8 million in Q1 2026; TTM through Mar 2026 was $3.0 million, a 225.47% increase from a year earlier, with the FY2025 full-year figure at $3.0 million, up 303.22% from the prior year.
• Change in Accured Expenses fell to -$2.8 million in Q1 2026 per AQST's latest filing, from $5.1 million in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $5.1 million in Q4 2025 and bottomed at -$4.0 million in Q1 2022.
• The 5-year median for Change in Accured Expenses is -$25000.0 (2022), against an average of -$362352.9.
• Biggest YoY gain for Change in Accured Expenses was 3916.0% in 2023; the steepest drop was 160.3% in 2023.
• Year by year, Change in Accured Expenses stood at -$25000.0 in 2022, then soared by 3916.0% to $954000.0 in 2023, then declined by 3.98% to $916000.0 in 2024, then soared by 455.68% to $5.1 million in 2025, then tumbled by 155.07% to -$2.8 million in 2026.
• Per Business Quant, the three latest AQST Change in Accured Expenses figures stand at -$2.8 million (Q1 2026), $5.1 million (Q4 2025), and $118000.0 (Q3 2025).